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Development and evaluation of a tri-functional lipid nanoparticles for treatment of HER2-
Positive breast cancer refractory to HER2 therapy
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Purpose: Breast cancer (BC) is the second leading cause of cancer deaths in women, and about 25% of BCs have overexpression 
of the HER2 receptor. Although HER2 targeted therapies have shown considerable improvement in HER2-positive BC patients’ 
outcome, treatment resistance remains a clinical challenge. Here, we sought to develop and evaluate a novel Tri-Functional Lipid 
Nano-Particulate (TFLP) drug delivery system that overcomes HER2 treatment resistance by dually targeting HER2 on BC cells and 
CD3 receptors on cytotoxic T-lymphocytes (CTLs).
Material and methods: Anti-HER2 (Trastuzumab) and anti-CD3 (OKT-3) antibodies, were conjugated to lipid nanoparticles by 
the micelle-transfer method, and the resulting formulation was purified by dextran gradient ultra-centrifugation. Targeted lipid 
nanoparticles were formulated with a fluorescent lipophilic dye, DiD, for studying receptor binding and internalization. Studies 
were conducted with HER2-positive BT474 cells and CD3-positive Jurkat cells using flow cytometry analyses. Doxorubicin HCl 
(DXR) was encapsulated in the nanoparticles by the remote-loading technique for cell-kill experiments. In vitro cell-kill studies were 
conducted by co-culturing BT474 as the target cells, and peripheral blood mononuclear cells as the effector cells, at varying ratios.
Results: Purified formulations were successfully characterized for conjugation by determining protein to lipid ratio. Flow cytometry 
analyses demonstrated successful cell binding and/or internalization of the TFLP with both the HER2 and CD3-positive cell lines. 
Moreover, these dual-targeted nanoparticles were able to retarget T cells to kill HER2 positive BC cells, and showed improved efficacy 
compared to non-targeted and plain HER2-targeted formulations in vitro.  
Conclusion: A novel TFLP drug delivery system that targets HER2 receptors on tumor cells, CD3 on CTLs, and is able to slowly 
release DXR was successfully developed and evaluated in vitro on HER2 overexpressing BC cells. Our findings show great promise 
at overcoming resistance to present HER2 targeted BC therapies, and may translate into improved anti-tumor activity clinically 
compared to other treatment options.
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The levels of vanadium in urine and blood can be used as biomarkers of exposure, but the mechanism of vanadium toxicity 
is of major relevance in order to understand how biomarkes can be valuable. Our research group has performed in vivo 
and in vitro studies using fish and rat models to analysed and compare the toxicity effects induce by vanadium(V) species 
in the forms of vanadate (V1) and decavanadate (V10). Vanadium toxicological studies often disregarded the formation of 
decameric vanadate species (V10) known to interact, in vitro, with high-affinity with many proteins such as myosin, actin and 
sarcoplasmic reticulum calcium pump. Among different experimental in vivo conditions, it was analysed different: (i) mode 
of administration; (ii) fish species; (iii) metal concentration (1 and 5 mM); (iv) tissues; (v) subcellular fractions ; (vi) exposure 
time and particularly different metal ionic species, such as V1 and V10. It was observed that‘‘decavanadate’’ promote different 
effects than other vanadate oligomers in catalase activity, glutathione content, lipid peroxidation, mitochondrial superoxide 
anion production and vanadium accumulation. Moreover, in in vitro studies using fish and rat liver mitochondria, it was 
observed that decavanadate impared respiration by depolarization of the mitochondrial membrane, wich altered the redox 
state of complex III. Putting it all together, it is suggested that decavanadate species are much more effective than monomeric 
vanadate species in inducing changes in several biomarkers. By changing mitochondrial functioning decavanadate migh 
provoke ROS formation, but further studies are needed to understand V10 contribution to vanadium biomarkers.
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